stockrowCorcept Therapeutics Incorporated
CORT Healthcare Biotechnology
Corcept Therapeutics Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $761.4 million, up 12.8% from fiscal 2024.
- Revenue
- +64.0%
- EPS
- +525.8%
- Free cash flow
- +161.0%
Quarter to September 2026, against a year earlier
Follow CORT
Alert me
Corcept Therapeutics Incorporated (CORT) EPS (diluted)
Corcept Therapeutics Incorporated's EPS (diluted) for fiscal 2025 was $0.82, down 33.3% from $1.23 in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.29. Over the past ten years it has ranged from −$0.06 (fiscal 2015) to $1.23 (fiscal 2024); the current reading is higher than 45% of that period. Corcept Therapeutics Incorporated ranks 34th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $0.82 | (33.33%) |
| FY2024 | $1.23 | 30.85% |
| FY2023 | $0.94 | 8.05% |
| FY2022 | $0.87 | (2.25%) |
| FY2021 | $0.89 | 4.71% |
| FY2020 | $0.85 | 10.39% |
| FY2019 | $0.77 | 28.33% |
| FY2018 | $0.60 | (42.31%) |
| FY2017 | $1.04 | 1,385.71% |
| FY2016 | $0.07 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.03 | 185.83% |
| Jun 2026 | $0.36 | — |
| Mar 2026 | −$0.30 | — |
| Dec 2025 | $0.20 | 25.00% |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| CORT Corcept Therapeutics Incorporated | $1.29 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$2.25 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
| ABVX Abivax SA Sponsored ADR compare | −$6.06 |
| PRAX Praxis Precision Medicines, Inc. compare | −$12.93 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on CORT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement